[go: up one dir, main page]

PE20121512A1 - Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa - Google Patents

Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa

Info

Publication number
PE20121512A1
PE20121512A1 PE2012000992A PE2012000992A PE20121512A1 PE 20121512 A1 PE20121512 A1 PE 20121512A1 PE 2012000992 A PE2012000992 A PE 2012000992A PE 2012000992 A PE2012000992 A PE 2012000992A PE 20121512 A1 PE20121512 A1 PE 20121512A1
Authority
PE
Peru
Prior art keywords
alkyl
gamma secretase
modulators
novelty
triazole derivatives
Prior art date
Application number
PE2012000992A
Other languages
English (en)
Inventor
Brandt Sven Franciscus Anna Van
Cleyn Michel Anna Jozef De
Henricus Jabobus Maria Gijsen
Didier Jean-Claude Berthelot
Michel Surkyn
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43569255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121512(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of PE20121512A1 publication Critical patent/PE20121512A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: HET1 ES UN HETEROCICLO DE FORMULA (a-1), (a-2), ENTRE OTROS; A1 ES CR9 O N; A2, A3 Y A4 SON INDEPENDIENTEMENTE CH O N SIEMPRE QUE MAXIMO DOS DE ELLOS SEAN N; L1 ES O, CARBONILO, NH(C=O), ENTRE OTROS; R1 ES CICLOALQUILO C3-7, ALQUENILO C2-6 O ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; L2 ES UN ENLACE DIRECTO, CARBONILO, O, S, ENTRE OTROS; R2 ES MORFOLINILO, PIPERIDINILO, PIPERAZINILO, ENTRE OTROS; R9 ES H, HALO O ALQUILOXI C1-4; R3 ES ALQUILO C1-4; R4, R5, Y R6 SON INDEPENDIENTEMENTE H, O ALQUILO C1-4; Xa ES CH O N; Xb ES O O S. SON COMPUESTOS PREFERIDOS: 5-(2-CLOROFENOXI)-N-[3-METOXI-4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL]-1-(1-METILETIL)-1H-1,2,4-TRIAZOL-3-AMINA; N-[3-METOXI-4-(2-METIL-4-PIRIDINIL)FENIL]-1-(1-METILETIL)-5-[3-(TRIFLUORMETIL)-1-PIPERIDINIL]-1H-1,2,4-TRIAZOL-3-AMINA.2.2HCL.2.7H2O; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHO COMPUESTO ES MODULADOR DE LA ENZIMA GAMMA SECRETASA UTIL PARA EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER, LESION CEREBRAL TRAUMATICA
PE2012000992A 2010-01-15 2011-01-12 Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa PE20121512A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10150892 2010-01-15
EP10171292 2010-07-29

Publications (1)

Publication Number Publication Date
PE20121512A1 true PE20121512A1 (es) 2012-12-06

Family

ID=43569255

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000991A PE20121511A1 (es) 2010-01-15 2011-01-12 Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
PE2012000992A PE20121512A1 (es) 2010-01-15 2011-01-12 Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000991A PE20121511A1 (es) 2010-01-15 2011-01-12 Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa

Country Status (21)

Country Link
US (2) US9145399B2 (es)
EP (2) EP2523955B1 (es)
JP (2) JP5824464B2 (es)
KR (2) KR20120123677A (es)
CN (2) CN102803261A (es)
AR (2) AR079904A1 (es)
AU (2) AU2011206635B2 (es)
BR (2) BR112012017310A2 (es)
CA (2) CA2784765A1 (es)
CL (2) CL2012001956A1 (es)
EA (2) EA021776B1 (es)
ES (2) ES2512840T3 (es)
IL (2) IL220840A (es)
MX (2) MX2012008259A (es)
NZ (2) NZ600648A (es)
PE (2) PE20121511A1 (es)
PH (2) PH12012501381A1 (es)
SG (2) SG182506A1 (es)
TW (2) TWI473807B (es)
WO (2) WO2011086099A1 (es)
ZA (2) ZA201205240B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2481715T3 (es) 2009-02-06 2014-07-31 Janssen Pharmaceuticals, Inc. Compuestos heterocíclicos bicíclicos sustituidos novedosos como moduladores de gamma-secretasa
AU2010262036B2 (en) 2009-05-07 2014-10-30 Cellzome Limited Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
BRPI1009637A2 (pt) * 2009-06-05 2019-04-30 Cephalon, Inc composto, composição e uso de um composto
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
CA2784765A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
SG188296A1 (en) * 2010-08-27 2013-04-30 Merck Patent Gmbh Triazolopyrazine derivatives
BR112013004746A2 (pt) 2010-09-02 2016-06-07 Takeda Pharmaceutical "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."
CN103502225B (zh) 2011-03-24 2015-11-25 杨森制药公司 作为γ分泌酶调节剂的经取代的三唑基哌嗪以及三唑基哌啶衍生物
AU2012285931B2 (en) 2011-07-15 2017-01-12 Cellzome Limited Novel substituted indole derivatives as gamma secretase modulators
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
JP6479476B2 (ja) * 2012-02-21 2019-03-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung SykチロシンキナーゼインヒビターおよびGCN2セリンキナーゼインヒビターとしての8−置換2−アミノー[1,2,4]トリアゾロ[1,5−A]ピラジン類
EP2822948B1 (en) * 2012-03-07 2016-04-06 Merck Patent GmbH Triazolopyrazine derivatives
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
KR102096625B1 (ko) 2012-05-16 2020-04-03 얀센 파마슈티칼즈, 인코포레이티드 (무엇보다도) 알츠하이머병의 치료에 유용한 치환 3,4-디하이드로-2h-피리도[1,2-a]피라진-1,6-디온 유도체
CN103508957B (zh) * 2012-06-25 2017-02-08 中国科学院上海药物研究所 羟乙基吡唑类化合物或氨乙基吡唑类化合物及其制备方法和用途
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
EP2687528A1 (en) 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
JOP20180012A1 (ar) * 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
KR102209418B1 (ko) 2012-12-20 2021-01-29 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체
CA2891755C (en) 2013-01-17 2021-10-26 Janssen Pharmaceutica Nv Substituted pyrido-piperazinone derivatives as gamma secretase modulators
DK3004079T3 (en) 2013-06-04 2018-04-16 Acturum Real Estate Ab PYRIMIDE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS
JP6368776B2 (ja) * 2013-06-04 2018-08-01 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
JP6396438B2 (ja) * 2013-06-04 2018-09-26 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
JP2016526534A (ja) 2013-06-11 2016-09-05 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジンのプロドラッグ誘導体
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
BR112017011644A2 (pt) 2014-12-05 2018-02-14 An2H Discovery Ltd métodos e composições de ativação da ligase parkina
KR101594470B1 (ko) 2015-05-28 2016-02-16 주식회사 네비엔 프리캐스트 콘크리트 슬래브 및 이들의 결합구조
KR101710943B1 (ko) 2016-05-13 2017-02-28 강태성 구조물용 피씨 데크 슬래브 및 이의 제조방법
CA3066110A1 (en) * 2016-06-03 2017-12-07 An2H Discovery Limited Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
JP7012715B2 (ja) * 2016-06-27 2022-01-28 エフ.ホフマン-ラ ロシュ アーゲー γ-セクレターゼモジュレーターとしてのトリアゾロピリジン
EP3481829B1 (en) 2016-07-08 2021-04-07 H. Hoffnabb-La Roche Ag Fused pyrimidine derivatives
EP3523304B1 (en) 2016-10-04 2021-01-27 H. Hoffnabb-La Roche Ag Bicyclic heteroaryl derivatives
WO2018087018A1 (en) 2016-11-08 2018-05-17 F. Hoffmann-La Roche Ag Phenoxytriazoles
US10889553B2 (en) 2017-12-01 2021-01-12 Nysnobio Ireland Dac Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
CN110194746B (zh) * 2018-02-26 2022-11-18 云南大学 用于治疗阿尔茨海默症的化合物,其制备方法和用途
CN110194743B (zh) * 2018-02-26 2022-11-11 云南大学 苯基(3-甲氧基-4-(4-甲基-1h-咪唑-1-基)苯基)甲酮类化合物
CN110194744B (zh) * 2018-02-26 2022-11-11 云南大学 一种抑制β-淀粉样蛋白生成的化合物及其制备方法和用途
US20230048657A1 (en) 2019-11-29 2023-02-16 Hoffmann-La Roche Inc. Process for the preparation of (9s)-2-bromo-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepine
AU2021393968A1 (en) 2020-12-11 2023-05-11 F. Hoffmann-La Roche Ag Process for the preparation of (9s)-n-[3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepin-2-amine and its solid form

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO1997003067A1 (en) 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
WO2000076969A1 (en) 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20030176454A1 (en) 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
DE10109867A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
EP1599472A1 (en) 2003-02-27 2005-11-30 F. Hoffmann-La Roche Ag Ccr-3 receptor antagonists
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
MXPA06001660A (es) 2003-08-14 2006-04-28 Hoffmann La Roche Moduladores gabanergicos.
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
AU2005297966B2 (en) 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
RU2008115499A (ru) 2005-09-22 2009-10-27 Санофи-Авентис (Fr) Новые производные аминокиламидов в качестве антагонистов лигандов рецепторов ccr3
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
EP2497796A3 (en) 2005-10-11 2012-12-26 Chemtura Corporation Diaromatic Amines
BRPI0618520A2 (pt) 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase
KR101464651B1 (ko) 2006-03-09 2014-11-24 에자이 알앤드디 매니지먼트 가부시키가이샤 다환식 신나미드 유도체
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
JP2010511019A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物
EP2061771A1 (en) 2006-12-12 2009-05-27 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
CN101631786A (zh) 2006-12-20 2010-01-20 先灵公司 新颖的jnk抑制剂
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
CA2676920A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
AU2008248129B8 (en) 2007-05-07 2013-05-30 Merck Sharp & Dohme Corp. Gamma secretase modulators
RU2009140182A (ru) 2007-05-11 2011-06-20 Ф. Хоффманн-Ля Рош Аг (Ch) Гетариланилины в качестве модуляторов для бета-амилоида
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
US20110053918A1 (en) 2007-06-29 2011-03-03 Zhaoning Zhu Gamma secretase modulators
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
WO2009028588A1 (ja) * 2007-08-31 2009-03-05 Eisai R & D Management Co., Ltd. 多環式化合物
EP2200990A1 (en) * 2007-09-06 2010-06-30 Schering Corporation Gamma secretase modulators
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
MX2010006243A (es) 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
JP2011506461A (ja) 2007-12-11 2011-03-03 シェーリング コーポレイション γ−セクレターゼモジュレーター
EP2257541B1 (en) * 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
CA2727036C (en) 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010054067A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
WO2010052199A1 (en) * 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
US8124766B2 (en) 2008-12-03 2012-02-28 Madrigal Pharmaceuticals, Inc. Inhibitors of diacylglycerol acyltransferase
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
ES2481715T3 (es) 2009-02-06 2014-07-31 Janssen Pharmaceuticals, Inc. Compuestos heterocíclicos bicíclicos sustituidos novedosos como moduladores de gamma-secretasa
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
CN102333777B (zh) 2009-02-26 2014-06-25 卫材R&D管理有限公司 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
WO2010100606A1 (en) 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
WO2010106745A1 (ja) 2009-03-16 2010-09-23 パナソニック株式会社 アプリケーション実行装置
KR20120028869A (ko) 2009-04-27 2012-03-23 하이 포인트 파마슈티칼스, 엘엘씨 β-세크레타제 억제제로서 치환된 이미다조[1,2-A]피리딘 유도체, 약제학적 조성물, 및 사용 방법
AU2010262036B2 (en) 2009-05-07 2014-10-30 Cellzome Limited Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
CA2784765A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
CN103502225B (zh) 2011-03-24 2015-11-25 杨森制药公司 作为γ分泌酶调节剂的经取代的三唑基哌嗪以及三唑基哌啶衍生物
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
AU2012285931B2 (en) 2011-07-15 2017-01-12 Cellzome Limited Novel substituted indole derivatives as gamma secretase modulators

Also Published As

Publication number Publication date
TW201134824A (en) 2011-10-16
NZ600648A (en) 2014-06-27
AR079904A1 (es) 2012-02-29
IL220838A0 (en) 2012-08-30
MX2012008259A (es) 2012-08-17
IL220840A (en) 2014-03-31
EP2523949B1 (en) 2014-08-20
CL2012001955A1 (es) 2012-11-30
WO2011086098A1 (en) 2011-07-21
AR079905A1 (es) 2012-02-29
KR20130028048A (ko) 2013-03-18
PH12012501381A1 (en) 2012-10-22
ZA201205240B (en) 2015-02-25
CN102906083A (zh) 2013-01-30
BR112012017442A2 (pt) 2016-04-19
EA201290654A1 (ru) 2012-12-28
ES2512840T3 (es) 2014-10-24
CA2784769A1 (en) 2011-07-21
CN102803261A (zh) 2012-11-28
CL2012001956A1 (es) 2013-01-25
TW201136918A (en) 2011-11-01
PE20121511A1 (es) 2012-12-06
JP2013517247A (ja) 2013-05-16
ES2523977T3 (es) 2014-12-03
US20120295901A1 (en) 2012-11-22
AU2011206634A1 (en) 2012-07-19
BR112012017310A2 (pt) 2016-04-19
US9079886B2 (en) 2015-07-14
NZ601150A (en) 2014-06-27
TWI491608B (zh) 2015-07-11
TWI473807B (zh) 2015-02-21
SG182506A1 (en) 2012-08-30
EP2523955B1 (en) 2014-07-16
EA201290655A1 (ru) 2012-12-28
CA2784765A1 (en) 2011-07-21
AU2011206635A1 (en) 2012-07-05
WO2011086099A1 (en) 2011-07-21
US9145399B2 (en) 2015-09-29
EP2523949A1 (en) 2012-11-21
US20120295891A1 (en) 2012-11-22
JP5824464B2 (ja) 2015-11-25
MX2012008260A (es) 2012-08-17
AU2011206634B2 (en) 2014-11-13
ZA201205245B (en) 2014-12-23
JP2013517246A (ja) 2013-05-16
AU2011206635B2 (en) 2015-01-22
EA022093B1 (ru) 2015-10-30
KR20120123677A (ko) 2012-11-09
EA021776B1 (ru) 2015-08-31
EP2523955A1 (en) 2012-11-21
PH12012501382A1 (en) 2012-10-22
SG182505A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
PE20121512A1 (es) Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa
PE20121442A1 (es) Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden
TW200637828A (en) Novel cis-imidazolines
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
EA201270166A1 (ru) Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20181919A1 (es) Amidas heterociclicas utiles como moduladores de proteinas
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
MA38380A1 (fr) Inhibiteurs quinazoline de l&#39;activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA35716B1 (fr) Formulations pharmaceutiques
MY154668A (en) 5-membered heterocyclic amides and related compounds
UY31431A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
TW200718358A (en) Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
PE20091400A1 (es) Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac
CO6241118A2 (es) Formas amorfas estabilizadas de mesilato de imatinib
SV2005002099A (es) &#34; nuevos compuestos &#34; ref. pc 32096a
MX344109B (es) Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
TN2012000132A1 (en) N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
UY27762A1 (es) Polimorfo del ácido 4-(2-(4-(1-(2-etoxietil)-1h-benzimidazol-2-ii)-1 - piperidinil)-alpha, alpha - dimetil -bencenoacético.

Legal Events

Date Code Title Description
FD Application declared void or lapsed